ENLIVEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.35 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 434.09K shares, a 335.57% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.92M shares, a 22.22% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 1.03M shares, a 668.15% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 121.51K shares, a 15.85% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.72M shares, a 51.36% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.46M shares, a 4.17% decline from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.56M shares, a 554.60% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 391.65K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 434.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 2.35M shares 10-Q · filed 2026-08-05 | 3.38M shares derived: sum of 3 quarters · filed 2026-08-05 | 3.51M shares derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | 1.92M shares 10-Q · filed 2026-05-07 | 2.95M shares derived: sum of 2 quarters · filed 2026-05-07 | 3.07M shares derived: sum of 3 quarters · filed 2026-05-07 | 3.17M shares derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | 1.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 1.15M shares derived: sum of 2 quarters · filed 2026-03-03 | 1.25M shares derived: sum of 3 quarters · filed 2026-03-03 | 3.72M shares 10-K · filed 2026-03-03 | |
| 2025-09-30 | 121.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 221.17K shares derived: sum of 2 quarters · filed 2025-11-12 | 2.69M shares 10-Q · filed 2025-11-12 | 2.82M shares derived: sum of 4 quarters · filed 2025-11-12 | |
| 2025-06-30 | 99.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 2.56M shares 10-Q · filed 2025-08-13 | 2.70M shares derived: sum of 3 quarters · filed 2025-08-13 | 2.84M shares derived: sum of 4 quarters · filed 2025-08-13 | |
| 2025-03-31 | 2.47M shares 10-Q · filed 2025-05-14 | 2.60M shares derived: sum of 2 quarters · filed 2025-05-14 | 2.74M shares derived: sum of 3 quarters · filed 2025-05-14 | 2.83M shares derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-12-31 | 134.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 278.78K shares derived: sum of 2 quarters · filed 2025-03-13 | 367.36K shares derived: sum of 3 quarters · filed 2025-03-13 | 2.46M shares 10-K · filed 2025-03-13 | |
| 2024-09-30 | 144.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 232.97K shares derived: sum of 2 quarters · filed 2024-11-13 | 2.32M shares 10-Q · filed 2024-11-13 | 2.37M shares derived: sum of 4 quarters · filed 2024-11-13 | |
| 2024-06-30 | 88.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 2.18M shares 10-Q · filed 2024-08-13 | 2.23M shares derived: sum of 3 quarters · filed 2024-08-13 | 2.58M shares derived: sum of 4 quarters · filed 2024-08-13 | |
| 2024-03-31 | 2.09M shares 10-Q · filed 2024-05-14 | 2.14M shares derived: sum of 2 quarters · filed 2024-05-14 | 2.49M shares derived: sum of 3 quarters · filed 2024-05-14 | 4.45M shares derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-12-31 | 48.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 398.30K shares derived: sum of 2 quarters · filed 2024-03-14 | 2.36M shares derived: sum of 3 quarters · filed 2024-03-14 | 2.56M shares 10-K · filed 2024-03-14 | |
| 2023-09-30 | 350.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.32M shares derived: sum of 2 quarters · filed 2023-11-09 | 2.52M shares 10-Q · filed 2023-11-09 | 2.41M shares derived: sum of 4 quarters · filed 2024-03-14 | |
| 2023-06-30 | 1.97M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 2.17M shares 10-Q · filed 2023-08-10 | 2.06M shares derived: sum of 3 quarters · filed 2024-03-14 | 2.06M shares derived: sum of 4 quarters · filed 2024-03-14 | |
| 2023-03-31 | 199.86K shares 10-Q · filed 2023-05-11 | 89.67K shares derived: sum of 2 quarters · filed 2024-03-14 | 89.67K shares derived: sum of 3 quarters · filed 2024-03-14 | 149.17K shares derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-12-31 | -110.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -110.19K shares derived: sum of 2 quarters · filed 2024-03-14 | -50.69K shares derived: sum of 3 quarters · filed 2024-03-14 | 391.65K shares 10-K · filed 2024-03-14 | 501.84K shares 10-K · filed 2023-02-10 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | 59.50K shares derived: sum of 2 quarters · filed 2022-10-25 | 501.84K shares 10-Q · filed 2022-10-25 | 1.83M shares derived: sum of 4 quarters · filed 2023-06-23 | |
| 2022-06-30 | 59.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 501.84K shares 10-Q · filed 2022-08-03 | 1.83M shares derived: sum of 3 quarters · filed 2023-06-23 | 2.00M shares derived: sum of 4 quarters · filed 2023-06-23 | |
| 2022-03-31 | 442.34K shares 10-Q · filed 2022-05-06 | 1.77M shares derived: sum of 2 quarters · filed 2023-06-23 | 1.94M shares derived: sum of 3 quarters · filed 2023-06-23 | 2.10M shares derived: sum of 4 quarters · filed 2023-06-23 | |
| 2021-12-31 | 1.33M shares derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | 1.50M shares derived: sum of 2 quarters · filed 2023-06-23 | 1.66M shares derived: sum of 3 quarters · filed 2023-06-23 | 2.19M shares 8-K · filed 2023-06-23 | 952.95K shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 168.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 331.65K shares derived: sum of 2 quarters · filed 2021-11-09 | 862.95K shares 10-Q · filed 2021-11-09 | 1.08M shares derived: sum of 4 quarters · filed 2021-11-09 | |
| 2021-06-30 | 162.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | 694.20K shares 10-Q · filed 2021-08-06 | 912.40K shares derived: sum of 3 quarters · filed 2021-08-06 | 1.13M shares derived: sum of 4 quarters · filed 2021-08-06 | |
| 2021-03-31 | 531.30K shares 10-Q · filed 2021-05-11 | 749.50K shares derived: sum of 2 quarters · filed 2021-05-11 | 968.00K shares derived: sum of 3 quarters · filed 2021-05-11 | 1.03M shares derived: sum of 4 quarters · filed 2021-05-11 | |
| 2020-12-31 | 218.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | 436.70K shares derived: sum of 2 quarters · filed 2021-03-05 | 502.16K shares derived: sum of 3 quarters · filed 2021-03-05 | 759.14K shares 10-K · filed 2021-03-05 | |
| 2020-09-30 | 218.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 283.96K shares derived: sum of 2 quarters · filed 2020-11-05 | 540.94K shares 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | 65.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | 322.44K shares 10-Q · filed 2020-08-14 | |||
| 2020-03-31 | 256.98K shares 10-Q · filed 2020-05-07 | ||||
| 2019-09-30 | 0.00 shares 10-Q · filed 2020-11-05 | ||||
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |